ClinicalTrials.gg
TerminatedNCT06790303Updated Jun 4, 2025Results posted

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

A Phase 2 interventional study of Feladilimab and Ipilimumab in Neoplasms, sponsored by GlaxoSmithKline. Terminated at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to low enrolment of participants

From the registry’s dates

  • Registered 3 years 10 months after the study started (first participant enrolled Mar 2021, registered Jan 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess the clinical activity of novel regimen (Feladilimab plus Ipilimumab) in participants with NSCLC.

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • NSCLC
  • Feladilimab
  • Iplimumab
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 8 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants capable of giving signed /assent.
  • Male or female, aged 18 years or older at the time consent is obtained. Participants in Korea must be age 19 years or older at the time consent is obtained.
  • Participants with or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) and
  • Participants capable of giving signed informed consent/assent.
  • Male or female, aged 18 years or older at the time consent is obtained. Participants in Korea must be age 19 years or older at the time consent is obtained.
  • Participants with histologically or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) and

    1. Documented disease progression based on radiographic imaging, during or after a maximum of 2 for locally/regionally advanced recurrent, Stage IIIb/Stage IIIc/Stage IV or disease. Two components of treatment must have been received in the same line or as separate lines of therapy: i) No more than or less than 1 line of platinum-containing chemotherapy regimen, and ii) No more than or less than 1 line of Programmed cell death ligand 1 (PD[L]1) monoclonal antibody (mAb) containing regimen.
    2. Participants with known V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) molecular alterations must have had disease progression after receiving the locally available SoC treatment for the molecular alteration.
    3. Participants who received prior anti-PD(L)1 therapy must fulfill the following requirements: i) Have achieved a CR, PR or SD and subsequently had disease progression (per 1.1 criteria) either on or after completing PD(L)1 therapy ii) Have not progressed or recurred within the first 12 weeks of PD(L)1 therapy, either clinically or per RECIST 1.1 criteria
  • , presenting with at least 1 measurable lesion per RECIST 1.1.
  • (ECOG) Performance Status (PS) score of 0 or 1.
  • A tumor tissue sample obtained at any time from the initial diagnosis of NSCLC to time of study entry is mandatory. Although a fresh tumor tissue sample obtained during screening is preferred, is acceptable.
  • Adequate organ function as defined in the protocol.
  • A male participant must agree to use a highly effective during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions apply:

    i) Not a woman of (WOCBP) or ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.

  • of at least 12 weeks.

Exclusion criteria

Exclusion Criteria:

  • Participants who received prior treatment with the following therapies (calculation is based on date of last therapy to date of first dose of study treatment):

    1. Docetaxel at any time.
    2. Any of the agents being tested in the current study.
    3. Systemic approved or investigational anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug is administered.
    4. Prior radiation therapy: permissible if at least one non-irradiated is available for assessment per version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least 2 weeks before start of study drug for radiation of any intended use is required.
  • Received greater than (>)2 for NSCLC, including participants with BRAF molecular alternations.
  • Invasive or history of invasive malignancy other than disease under study within the last 2 years, except

    • Any other invasive malignancy for which the participant was definitively treated, has been disease-free for at least 2 years and in the opinion of the principal investigator and GlaxoSmithKline Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical trial.
    • Curatively treated non-melanoma skin cancer or successfully treated in situ carcinoma.
  • Carcinomatous meningitis (regardless of clinical status) and uncontrolled or symptomatic Central nervous system (CNS) .
  • Major surgery less than or equal to (\<=) 28 days of first dose of study treatment.
  • disease (current or history) or syndrome that required systemic treatment within the past 2 years. Replacement therapies which include physiological doses of for treatment of endocrinopathies (for example, adrenal insufficiency) are not considered systemic treatments.
  • Receiving systemic steroids (>10 milligrams [mg]) oral prednisone or equivalent) or other agents within 7 days prior to first dose of study treatment.
  • Prior allogeneic/autologous bone marrow or solid organ transplantation.
  • Receipt of any within 30 days prior to first dose of study treatment.
  • Toxicity from previous anticancer treatment that includes:

    1. Greater than or equal to (>=) Grade 3 toxicity considered related to prior immunotherapy and that led to treatment discontinuation.
    2. Toxicity related to prior treatment that has not resolved to \<= Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be \<= Grade 2).
  • History (current and past) of idiopathic pulmonary fibrosis, pneumonitis (for past- pneumonitis exclusion only if steroids were required for treatment), interstitial lung disease, or organizing pneumonia.
  • Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural or pericardial effusions.
  • Recent history (within the past 6 months) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess.
  • History or evidence of cardiac abnormalities within the 6 months prior to enrollment which include

    1. Serious, uncontrolled cardiac arrhythmia or abnormalities including second degree (Type II) or third degree atrioventricular block.
    2. Cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting or bypass grafting.
    3. Symptomatic pericarditis.
  • Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypo-albuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
  • Active infection requiring systemic therapy \<=7 days prior to first dose of study treatment.
  • Participants with known infection.
  • Participants with history of severe to mAb or hypersensitivity to any of the study treatment(s) or their .
  • Participants requiring ongoing therapy with a medication that is a strong inhibitor or inducer of the cytochrome P 3A4 () enzymes.
  • Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other condition that could interfere with participant's safety, obtaining , or compliance to the study procedures in the opinion of the investigator.
  • Pregnant or lactating female participants.
  • Participant who is currently participating in or has participated in a study of an investigational device within 4 weeks prior to the first dose of study treatment.
  • Participants with presence of surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.
  • Participants with positive antibody test result at screening or within 3 months prior to first dose of study intervention.
  • Participants with positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment.
  • Receipt of transfusion of blood products (including or red blood cells) or administration of colony-stimulating factors (including granulocyte colony stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor, and recombinant erythropoietin) within 14 days before the first dose of study intervention.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Feladilimab plus Ipilimumab

    Drug: Feladilimab · Drug: Ipilimumab

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

    Time frame: Up to 29 weeks

  2. Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)

    Criteria for dose-limiting toxicity (DLT) included hematologic indicators such as febrile neutropenia as defined by CTCAE v5; Grade 4 neutropenia of \>7 days in duration; Grade 4 anemia and Grade 3-4 thrombocytopenia with bleeding. Non-hematologic criteria, comprising Grade 4 toxicity; Grade 3 pneumonitis of any duration; Grade 3 toxicity that does not resolve to ≤Grade 1 or baseline within 3 days despite optimal supportive care; any Grade 2 ocular toxicity requiring systemic steroids, or any ≥ Grade 3 ocular toxicity Any other toxicity considered to be dose-limiting that occurs beyond four weeks was considered as DLT. Any other event which in the judgment of the investigator and GSK Medical Monitor is considered to be a DLT.

    Time frame: Up to 21 days

  3. Part 1: Number of Participants With Worst-case Change Post-baseline in Hematology Parameters

    Blood samples were collected for evaluation of hematology parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

    Time frame: Baseline (Day 1) and up to 29 weeks

  4. Part 1: Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters

    Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

    Time frame: Baseline (Day 1) and up to 29 weeks

  5. Part 1: Number of Participants With Worst Case Change Post-baseline in Urinalysis Parameters

    Urine samples were collected for evaluation of urinalysis parameters using dipstick method. The dipstick test gave results in a semi-quantitative manner. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with 'Any increase', or 'no changes/decreased' values have been presented.

    Time frame: Baseline (Day 1) and up to 29 weeks

  6. Part 1: Change From Baseline in Potential of Hydrogen (pH) of Urine

    Urine samples were collected from participants to assess urine pH levels. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Changes from baseline in urine pH were reported.

    Time frame: Baseline (Day 1), week 4, week 7, week 10, week 13 and week 29 (Treatment Discontinuation)

  7. Part 1: Change From Baseline in Specific Gravity of Urine

    Urine samples were collected from participants to analyze urine specific gravity. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Changes from baseline in specific gravity of urine were reported.

    Time frame: Baseline (Day 1), week 4, week 7, week 10, week 13 and week 29 (Treatment Discontinuation)

  8. Part 1: Number of Participants With AE Leading to Dose Modifications

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. The number of participants who experienced AE leading to dose modifications were evaluated.

    Time frame: Up to 29 weeks

  9. Part 2: Overall Survival

    OS is defined as the time from randomization until death due to any cause.

    Time frame: Up to 29 weeks

Secondary outcomes

  1. Part 1: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who had a confirmed complete response (CR) or confirmed partial response (PR) as their best overall response (BOR) recorded from the date of randomization until disease progression or initiation of new anti-cancer therapy, whichever is earlier based on blinded independent central review (BICR) evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeter in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters (e.g., percent change from baseline).

    Time frame: Up to 29 weeks

  2. Part 1: Disease Control Rate (DCR)

    DCR was defined as the percentage of participants with a confirmed CR + PR at any time, plus stable disease (SD) \>=12 weeks. PR was defined as at least 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. Stable Disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

    Time frame: Up to 29 weeks

  3. Part 1: Maximum Concentration (Cmax) and Minimum Concentration (Cmin)

    Blood samples were collected for PK analysis.

    Time frame: Up to 29 weeks

  4. Part 2: Milestone Survival Rate at 12 and 18 Months

    Milestone survival rate is the proportion of participants who are alive at a specific, predefined point in time after a certain event or diagnosis post treatment.

    Time frame: At 12 and 18 months

  5. Part 2: Number of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD) Based on RECIST 1.1

    Complete Response \[CR\], Partial Response \[PR\], stable disease \[SD\], and progressive disease (PD) as assessed by the investigator per IMWG. CR defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm; PR was defined as at least 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters; Stable Disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started.

    Time frame: Up to 29 weeks

  6. Part 2: Number of Participants With iRECIST Complete Response (iCR), iRECIST Partial Response (iPR), iRECIST Stable Disease (iSD), iRECIST Confirmed Progressive Disease (iCPD), and iRECIST Unconfirmed Progressive Disease (iUPD)

    Modified RECIST 1.1 for immune-based therapeutics (iRECIST) is based on RECIST v 1.1 but adapted to account for the unique tumor response seen with immunotherapeutic drugs. iRECIST was to be used to assess tumor response and progression and make treatment decisions. iCR: disappearance of all target lesions; iPR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). iCPD: either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; iSD: stable disease in the absence of CR or PD and iUPD: unconfirmed progressive disease when PD is unconfirmed.

    Time frame: Up to 29 weeks

  7. Part 2: Number of Participants With PFS, ORR, DOR, and DCR

    PFS defined as time from the date of randomization to the date of disease progression or death, whichever will occurs earlier, per RECIST criteria. ORR defined as the percentage of participants with a confirmed CR or PR at any time per RECIST criteria. DOR defined as the time from first documented evidence of CR or PR until disease progression or death, per RECIST criteria. DCR was defined as the percentage of participants with a confirmed CR + PR at any time, plus stable disease (SD) \>=12 weeks.

    Time frame: Up to 29 weeks

  8. Part 2: Number of Participants With iPFS, iORR, and iDOR

    iPFS defined as time from the date of randomization to the date of disease progression or death, whichever will occurs earlier, per iRECIST criteria. iORR defined as the percentage of participants with a confirmed iCR or iPR at any time per iRECIST criteria. iDOR defined as the time from first documented evidence of CR or PR until disease progression or death, per iRECIST criteria.

    Time frame: Up to 29 weeks

  9. Part 2: Number of Participants With AEs and SAEs

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. AEs and SAEs were planned to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

    Time frame: Up to 29 weeks

  10. Part 2: Number of Participants With AESI

    Number of participants with AESI were planned to be evaluated.

    Time frame: Up to 29 weeks

  11. Part 2: Number of Participants With AEs and SAEs Leading to Dose Modification

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. AEs and SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. Number of participants with AEs and SAEs leading to dose modification (delays/withdrawal) were planned to be evaluated.

    Time frame: Up to 29 weeks

  12. Part 2: Number of Participants With Clinically Significant Changes in Hematology Lab Parameters

    Blood samples were to be collected for the analysis of hematology parameters. The laboratory parameters were to be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade were to be defined relative to the Baseline grade.

    Time frame: Up to 29 weeks

  13. Part 2: Number of Participants With Clinically Significant Changes in Clinical Chemistry Lab Parameters

    Blood samples were to be collected for the analysis of chemistry parameters. The laboratory parameters were to be graded according to CTCAE version 5. G1: mild; G2: moderate; G3: severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade were to be defined relative to the Baseline grade.

    Time frame: Up to 29 weeks

  14. Part 2: Number of Participants With Clinically Significant Changes in Vital Signs

    Vital signs were planned to be measured after 5 minutes of rest and taken in the same position throughout the study.

    Time frame: Up to 29 weeks

  15. Part 2: Maximum Concentration (Cmax) and Minimum Concentration (Cmin)

    Blood samples were planned to be collected for PK analysis.

    Time frame: Up to 29 weeks

  16. Part 2: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Feladilimab

    Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays.

    Time frame: Up to 29 weeks

  17. Part 2: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Iplimumab

    Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays.

    Time frame: Up to 29 weeks

07

Results

Posted Jun 4, 2025

Participant flow

This is a sub-study of the master study NCT03739710. This sub study was terminated due to low enrolment of participants. The study was planned to include two phases - Part 1 and Part 2. No participants from this sub study were enrolled in part 2 as study was early terminated.

Participant flow — Overall Study
MilestoneFeladilimab + Ipilimumab
Started8
Completed0
Not completed8
Withdrew: Study terminated by sponsor4
Withdrew: Death4

Outcome measures

PrimaryPart 1: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Time frame:
Up to 29 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsFeladilimab + Ipilimumab
Any AE8
Any SAE3
PrimaryPart 1: Number of Participants With Dose Limiting Toxicities (DLTs)

Criteria for dose-limiting toxicity (DLT) included hematologic indicators such as febrile neutropenia as defined by CTCAE v5; Grade 4 neutropenia of \>7 days in duration; Grade 4 anemia and Grade 3-4 thrombocytopenia with bleeding. Non-hematologic criteria, comprising Grade 4 toxicity; Grade 3 pneumonitis of any duration; Grade 3 toxicity that does not resolve to ≤Grade 1 or baseline within 3 days despite optimal supportive care; any Grade 2 ocular toxicity requiring systemic steroids, or any ≥ Grade 3 ocular toxicity Any other toxicity considered to be dose-limiting that occurs beyond four weeks was considered as DLT. Any other event which in the judgment of the investigator and GSK Medical Monitor is considered to be a DLT.

Time frame:
Up to 21 days
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsFeladilimab + Ipilimumab
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)2
PrimaryPart 1: Number of Participants With Worst-case Change Post-baseline in Hematology Parameters

Blood samples were collected for evaluation of hematology parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Time frame:
Baseline (Day 1) and up to 29 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst-case Change Post-baseline in Hematology Parameters
ParticipantsFeladilimab + Ipilimumab
Basophils, Decrease to Low0
Basophils, Change to Normal or No Change8
Basophils, Increase to High0
Eosinophils, Decrease to Low0
Eosinophils, Change to Normal or No Change7
Eosinophils, Increase to High1
Erythrocytes, Decrease to Low2
Erythrocytes, Change to Normal or No Change6
Erythrocytes, Increase to High0
Hemoglobin, Decrease to Low0
Hemoglobin, Change to Normal or No Change8
Hemoglobin, Increase to High0
Ery. Mean Corpuscular HGB Concentration (EMCHC), Decrease to Low1
EMCHC, Change to Normal or No Change7
EMCHC, Increase to High0
Ery. Mean Corpuscular Hemoglobin (EMCH), Decrease to Low0
EMCH, Change to Normal or No Change7
EMCH, Increase to High1
Ery. Mean Corpuscular Volume (EMCV), Decrease to Low0
EMCV, Change to Normal or No Change7
EMCV, Increase to High1
Hematocrit, Decrease to Low0
Hematocrit, Change to Normal or No Change8
Hematocrit, Increase to High0
Leukocytes, Decrease to Low0
Leukocytes, Change to Normal or No Change7
Leukocytes, Increase to High1
Lymphocytes, Decrease to Low0
Lymphocytes, Change to Normal or No Change8
Lymphocytes, Increase to High0
Monocytes, Decrease to Low0
Monocytes, Change to Normal or No Change7
Monocytes, Increase to High1
Neutrophils, Decrease to Low0
Neutrophils, Change to Normal or No Change6
Neutrophils, Increase to High2
Platelets, Decrease to Low1
Platelets, Change to Normal or No Change6
Platelets, Increase to High1
PrimaryPart 1: Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters

Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.

Time frame:
Baseline (Day 1) and up to 29 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters
ParticipantsFeladilimab + Ipilimumab
Alanine aminotransferase (ALT), Decrease to Low0
ALT, Change to Normal or No Change6
ALT, Increase to High2
Albumin, Decrease to Low2
Albumin, Change to Normal or No Change6
Albumin, Increase to High0
Alkaline Phosphatase (AP), Decrease to Low0
AP, Change to Normal or No Change8
AP, Increase to High0
Aspartate Aminotransferase (AST), Decrease to Low0
AST, Change to Normal or No Change8
AST, Increase to High0
Bilirubin, Decrease to Low0
Bilirubin, Change to Normal or No Change8
Bilirubin, Increase to High0
C Reactive Protein (mg/L), Decrease to Low0
C Reactive Protein, Change to Normal or No Change3
C Reactive Protein, Increase to High0
Calcium, Decrease to Low0
Calcium, Change to Normal or No Change7
Calcium, Increase to High1
Creatinine, Decrease to Low1
Creatinine, Change to Normal or No Change6
Creatinine, Increase to High1
Glucose, Decrease to Low0
Glucose, Change to Normal or No Change7
Glucose, Increase to High1
Lactate Dehydrogenase (LDH), Decrease to Low0
LDH, Change to Normal or No Change8
LDH, Increase to High0
Potassium, Decrease to Low1
Potassium, Change to Normal or No Change7
Potassium, Increase to High0
Protein, Decrease to Low1
Protein, Change to Normal or No Change7
Protein, Increase to High0
Sodium, Decrease to Low1
Sodium, Change to Normal or No Change7
Sodium, Increase to High0
Thyrotropin, Decrease to Low0
Thyrotropin, Change to Normal or No Change5
Thyrotropin, Increase to High2
Triiodothyronine, Free, Decrease to Low1
Triiodothyronine, Free, Change to Normal or No Change3
Triiodothyronine, Free, Increase to High0
Troponin T, Decrease to Low0
Troponin T, Change to Normal or No Change2
Troponin T, Increase to High1
Urea, Decrease to Low0
Urea, Change to Normal or No Change3
Urea, Increase to High5
PrimaryPart 1: Number of Participants With Worst Case Change Post-baseline in Urinalysis Parameters

Urine samples were collected for evaluation of urinalysis parameters using dipstick method. The dipstick test gave results in a semi-quantitative manner. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with 'Any increase', or 'no changes/decreased' values have been presented.

Time frame:
Baseline (Day 1) and up to 29 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst Case Change Post-baseline in Urinalysis Parameters
ParticipantsFeladilimab + Ipilimumab
Occult Blood, No Change/Decreased6
Protein, Any Increase3
Protein, No Change/Decreased3
PrimaryPart 1: Change From Baseline in Potential of Hydrogen (pH) of Urine

Urine samples were collected from participants to assess urine pH levels. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Changes from baseline in urine pH were reported.

Time frame:
Baseline (Day 1), week 4, week 7, week 10, week 13 and week 29 (Treatment Discontinuation)
Reported as:
Mean · Potential of Hydrogen (pH)
Part 1: Change From Baseline in Potential of Hydrogen (pH) of Urine
Potential of Hydrogen (pH)Feladilimab + Ipilimumab
Baseline (Day 1)6.33 ± 0.816
WEEK 4-0.80 ± 0.975
WEEK 7-0.50 ± 0.707
WEEK 100.00 ± NA
WEEK 130.50 ± NA
WEEK 29 (Treatment Discontinuation)-0.50 ± 0.866
PrimaryPart 1: Change From Baseline in Specific Gravity of Urine

Urine samples were collected from participants to analyze urine specific gravity. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Changes from baseline in specific gravity of urine were reported.

Time frame:
Baseline (Day 1), week 4, week 7, week 10, week 13 and week 29 (Treatment Discontinuation)
Reported as:
Mean · Kilogram per cubic meter
Part 1: Change From Baseline in Specific Gravity of Urine
Kilogram per cubic meterFeladilimab + Ipilimumab
Baseline (Day 1)1.0175 ± 0.00418
WEEK 40.0050 ± 0.01173
WEEK 70.0150 ± 0.01414
WEEK 100.0000 ± NA
WEEK 130.0250 ± NA
WEEK 29 (Treatment Discontinuation)0.0017 ± 0.00764
PrimaryPart 1: Number of Participants With AE Leading to Dose Modifications

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. The number of participants who experienced AE leading to dose modifications were evaluated.

Time frame:
Up to 29 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With AE Leading to Dose Modifications
ParticipantsFeladilimab + Ipilimumab
Part 1: Number of Participants With AE Leading to Dose Modifications1
PrimaryPart 2: Overall Survival

OS is defined as the time from randomization until death due to any cause.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 1: Overall Response Rate (ORR)

ORR was defined as the percentage of participants who had a confirmed complete response (CR) or confirmed partial response (PR) as their best overall response (BOR) recorded from the date of randomization until disease progression or initiation of new anti-cancer therapy, whichever is earlier based on blinded independent central review (BICR) evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeter in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters (e.g., percent change from baseline).

Time frame:
Up to 29 weeks
Reported as:
Number · Percentage of participants
Part 1: Overall Response Rate (ORR)
Percentage of participantsFeladilimab + Ipilimumab
Complete response0 (0 to 0)
Partial response0 (0 to 0)
SecondaryPart 1: Disease Control Rate (DCR)

DCR was defined as the percentage of participants with a confirmed CR + PR at any time, plus stable disease (SD) \>=12 weeks. PR was defined as at least 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. Stable Disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 1: Maximum Concentration (Cmax) and Minimum Concentration (Cmin)

Blood samples were collected for PK analysis.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Milestone Survival Rate at 12 and 18 Months

Milestone survival rate is the proportion of participants who are alive at a specific, predefined point in time after a certain event or diagnosis post treatment.

Time frame:
At 12 and 18 months

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD) Based on RECIST 1.1

Complete Response \[CR\], Partial Response \[PR\], stable disease \[SD\], and progressive disease (PD) as assessed by the investigator per IMWG. CR defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm; PR was defined as at least 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters; Stable Disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With iRECIST Complete Response (iCR), iRECIST Partial Response (iPR), iRECIST Stable Disease (iSD), iRECIST Confirmed Progressive Disease (iCPD), and iRECIST Unconfirmed Progressive Disease (iUPD)

Modified RECIST 1.1 for immune-based therapeutics (iRECIST) is based on RECIST v 1.1 but adapted to account for the unique tumor response seen with immunotherapeutic drugs. iRECIST was to be used to assess tumor response and progression and make treatment decisions. iCR: disappearance of all target lesions; iPR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). iCPD: either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; iSD: stable disease in the absence of CR or PD and iUPD: unconfirmed progressive disease when PD is unconfirmed.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With PFS, ORR, DOR, and DCR

PFS defined as time from the date of randomization to the date of disease progression or death, whichever will occurs earlier, per RECIST criteria. ORR defined as the percentage of participants with a confirmed CR or PR at any time per RECIST criteria. DOR defined as the time from first documented evidence of CR or PR until disease progression or death, per RECIST criteria. DCR was defined as the percentage of participants with a confirmed CR + PR at any time, plus stable disease (SD) \>=12 weeks.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With iPFS, iORR, and iDOR

iPFS defined as time from the date of randomization to the date of disease progression or death, whichever will occurs earlier, per iRECIST criteria. iORR defined as the percentage of participants with a confirmed iCR or iPR at any time per iRECIST criteria. iDOR defined as the time from first documented evidence of CR or PR until disease progression or death, per iRECIST criteria.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With AEs and SAEs

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. AEs and SAEs were planned to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With AESI

Number of participants with AESI were planned to be evaluated.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With AEs and SAEs Leading to Dose Modification

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. AEs and SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. Number of participants with AEs and SAEs leading to dose modification (delays/withdrawal) were planned to be evaluated.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With Clinically Significant Changes in Hematology Lab Parameters

Blood samples were to be collected for the analysis of hematology parameters. The laboratory parameters were to be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade were to be defined relative to the Baseline grade.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With Clinically Significant Changes in Clinical Chemistry Lab Parameters

Blood samples were to be collected for the analysis of chemistry parameters. The laboratory parameters were to be graded according to CTCAE version 5. G1: mild; G2: moderate; G3: severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade were to be defined relative to the Baseline grade.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With Clinically Significant Changes in Vital Signs

Vital signs were planned to be measured after 5 minutes of rest and taken in the same position throughout the study.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Maximum Concentration (Cmax) and Minimum Concentration (Cmin)

Blood samples were planned to be collected for PK analysis.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Feladilimab

Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Iplimumab

Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays.

Time frame:
Up to 29 weeks

No measurements were reported for this outcome.

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to 29 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Feladilimab + Ipilimumab4/8 (50%)3/8 (37.5%)8/8 (100%)
Most frequent serious events
Most frequent serious events
EventFeladilimab + Ipilimumab
PyrexiaGeneral disorders1/8
Pneumonia staphylococcalInfections and infestations1/8
OverdoseInjury, poisoning and procedural complications1/8
HypercalcaemiaMetabolism and nutrition disorders1/8
Spinal cord compressionNervous system disorders1/8
Subacute inflammatory demyelinating polyneuropathyNervous system disorders1/8
Confusional statePsychiatric disorders1/8
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders1/8
Most frequent other events
Showing 10 of 24
Most frequent other events
EventFeladilimab + Ipilimumab
AnaemiaBlood and lymphatic system disorders2/8
Abdominal painGastrointestinal disorders2/8
ConstipationGastrointestinal disorders2/8
ArthralgiaMusculoskeletal and connective tissue disorders2/8
LymphopeniaBlood and lymphatic system disorders1/8
Abdominal distensionGastrointestinal disorders1/8
General physical health deteriorationGeneral disorders1/8
BronchitisInfections and infestations1/8
Oral fungal infectionInfections and infestations1/8
Pneumonia klebsiellaInfections and infestations1/8

Baseline characteristics

Age, Customized
Age, Customized(Participants)Feladilimab + Ipilimumab
18 to 84 years8
Sex: Female, Male
Sex: Female, Male(Participants)Feladilimab + Ipilimumab
Female3
Male5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Feladilimab + Ipilimumab
All other races8
08

Study locations

3 sites
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Brampton, Ontario L6R3J7, Canada
  • GSK Investigational Site
    Bordeaux, 33076, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Sep 2021, 6 months.

Results were first posted in Jun 2025, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Jan 24, 2025
StartActual
Mar 4, 2021
Primary completionActual
Sep 23, 2021
CompletionActual
Sep 23, 2021
Results first posted
Jun 4, 2025
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06790303
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 24, 2025
Start date
Mar 4, 2021
Primary completion
Sep 23, 2021
Completion
Sep 23, 2021
Results posted
Jun 4, 2025
Last update
Jun 4, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Feladilimab

Start the discussion